Table 2.
Proportion of patients who suffered a hip fracture and were prescribed antiosteoporotic treatment* within 90 days after hospital discharge
| Basque Country (2017–2021) | Catalonia (2010–2018) | Navarre (2014–2021) | Valencia Region (2008–2020) | PREV2FO National Cohort | |
|---|---|---|---|---|---|
| Treatment for the study period | |||||
| N | 9519 | 56,627 | 4419 | 50,905 | 121,470 |
| Any antiosteoporotic medication (%) | 37.4 | 18.9 | 25.4 | 22.0 | 21.9 |
| Drug classes prescribed (%) | |||||
| Oral bisphosphonates | 18.1 | 14.2 | 7.9 | 12.8 | 13.7 |
| Denosumab | 16.6 | 2.0 | 16.3 | 4.0 | 4.5 |
| Teriparatide/PTH | 2.7 | 1.3 | 1.2 | 2.7 | 2.0 |
| Other | 0.0 | 1.4 | 0.1 | 2.4 | 1.7 |
*At least one prescription within 90 days after hospital discharge